From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Year | |||||
---|---|---|---|---|---|
2004 | 2005 | 2006 | 2007 | 2008 | |
Concomitant LABA and ICS users | 123,873 (52.0%) | 152,857 (54.6%) | 152,418 (53.3%) | 172,225 (55.3%) | 177,159 (57.6%) |
Switchers | 12,785 (5.4%) | 13,266 (4.7%) | 14,207 (5.0%) | 14,446 (4.6%) | 14,899 (4.8%) |
Non-concomitant LABA and ICS users | 1,314 (0.6%) | 1,686 (0.6%) | 1,992 (0.7%) | 1,896 (0.6%) | 1,936 (0.6%) |
LABA users without ICS | 15,612 (6.5%) | 19,200 (6.9%) | 18,193 (6.4%) | 17,810 (5.7%) | 16,749 (5.4%) |
ICS users without LABA | 84,818 (35.6%) | 92,970 (33.2%) | 99,334 (34.7%) | 105,252 (33.8%) | 96,615 (31.4%) |